Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Sagittarius Life Science (3205) - Total Liabilities
Latest total liabilities as of September 2025: NT$57.75 Million TWD
Based on the latest financial reports, Sagittarius Life Science (3205) has total liabilities worth NT$57.75 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sagittarius Life Science - Total Liabilities Trend (2015–2024)
This chart illustrates how Sagittarius Life Science's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sagittarius Life Science Competitors by Total Liabilities
The table below lists competitors of Sagittarius Life Science ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S.Y.PANEL Co Ltd
KQ:109610
|
Korea | ₩241.40 Billion |
|
CIG WIRELESS
F:6CW
|
Germany | €72.35 Million |
|
Digital China Holdings Limited
TW:910861
|
Taiwan | NT$13.81 Billion |
|
Jiin Ming Industry Co Ltd
TWO:3230
|
Taiwan | NT$345.61 Million |
|
OUTSURANCE GROUP LTD
JSE:OUT
|
South Africa | ZAC22.70 Billion |
|
Tu Liem Urban Development JSC
VN:NTL
|
Vietnam | ₫272.06 Billion |
|
Prolific Technology
TWO:6233
|
Taiwan | NT$154.32 Million |
|
Sumiseki HoldingsInc.
PINK:SMSKF
|
USA | $3.42 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Sagittarius Life Science's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sagittarius Life Science's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sagittarius Life Science (2015–2024)
The table below shows the annual total liabilities of Sagittarius Life Science from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$100.07 Million | -27.40% |
| 2023-12-31 | NT$137.82 Million | +11.41% |
| 2022-12-31 | NT$123.70 Million | -14.11% |
| 2021-12-31 | NT$144.03 Million | -5.46% |
| 2020-12-31 | NT$152.36 Million | +11.14% |
| 2019-12-31 | NT$137.09 Million | +42.24% |
| 2018-12-31 | NT$96.38 Million | -0.80% |
| 2017-12-31 | NT$97.16 Million | -51.54% |
| 2016-12-31 | NT$200.51 Million | -51.91% |
| 2015-12-31 | NT$416.95 Million | -- |